"Semaglutide and Wegovy: Promising Heart Health Benefits Unveiled in New Studies"

Semaglutide, the active ingredient in weight loss drugs like Wegovy and Ozempic, has been found to reduce the risk of heart attacks and strokes by 20% in overweight individuals with pre-existing cardiovascular disease but without Type 2 diabetes, according to a study of over 17,000 people. The research, published in the New England Journal of Medicine, highlights the potential benefits of semaglutide beyond its initial use for diabetes treatment. Semaglutide has gained attention for its role in weight loss, and while Ozempic is approved for Type 2 diabetes, both Ozempic and Wegovy (a higher-dosage version of Ozempic) can be prescribed off-label for chronic weight management. The drug works by slowing down digestion and reducing appetite. Additionally, semaglutide has shown potential anti-inflammatory and blood-thinning effects, contributing to its cardiovascular benefits when combined with weight loss.